Impact Factor
2.83
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
0.87
2,156 total citations
h5-index
50
h5 depth signal
Cited share
24.2%
633 of 2,620
Total citations
2,156
Citation footprint
Metric signal
0.91
External metric anchor
Self-citation
2.8%
60 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
Japan
1,968
United States
1,942
Italy
1,401
India
938
China
811
Citing Fields of Research
Neurodegenerative Disorders
4,619
Brain Neurological Disorders
3,111
Neuromuscular Disorders
2,754
Nervous System Disorders
2,659
Vascular Disorders
2,117
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
40,537
Articles tracked across the journal lifetime
Indexed publication set
2,620
633 cited publications
Last 12 months
2,367
197.3 publications/month
Open access share
4.1%
96 OA publications in the last year
Leading citing country
Japan
1,968 citing publications
Leading citing field
Neurodegenerative Disorders
4,619 citing publications
Latest tracked publication
16 October 2026
10 recent records available
Coverage & Indexing History
v2n1,Jan./Feb. 1965-
v2n1,Jan./Feb. 1965-
Active Coverage
Active Coverage
Research Focus & Classification
Indexed Subjects
Neurodegenerative Disorders
Neuromuscular Disorders
Brain Neurological Disorders
Vascular Disorders
Nervous System Disorders
Issuing & Sponsoring Bodies
Contributor
World Federation of Neurology
Broad Categories
Neurology
Neurodegenerative Disorders
Neuromuscular Disorders
Vascular Disorders
Brain Neurological Disorders
Musculoskeletal Disorders
MeSH Descriptors
Neurology
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1016/j.jns.2026.126224
Open DOI
Data-driven progression trajectories across clinical subtypes of amyotrophic lateral sclerosis
02
DOI 10.1016/j.jns.2026.126218
Open DOI
Reply to: From cytokine discrimination to penetrance prediction in moyamoya disease: Comment on Park et al.
03
04
DOI 10.1016/j.jns.2026.126222
Open DOI
Reply to: Comment on “Plasma signatures of type 2 inflammation and vascular remodeling in moyamoya disease”
05
06
07
DOI 10.1016/j.jns.2026.126217
Open DOI
From cytokine discrimination to penetrance prediction in moyamoya disease: Comment on Park et al.
08
DOI 10.1016/j.jns.2026.126219
Open DOI
Reply to: Incremental value of a three-cytokine signature beyond IL-1β in moyamoya disease
09
DOI 10.1016/j.jns.2026.126221
Open DOI
Comment on “Plasma signatures of type 2 inflammation and vascular remodeling in moyamoya disease”
10
DOI 10.1016/j.jns.2026.126220
Open DOI
Incremental value of a three-cytokine signature beyond IL-1β in moyamoya disease
Bibliographical & Catalog Notes
Also available online.
Text in English, German, Spanish, or French, with summaries in two of these languages.
Official bulletin of the World Federation of Neurology.
Vol. 92, no. 1 (JUL 1989)19900917 Notice published Printed on acid-free paper